Quantitative benefit-risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with m<i>IDH1</i> cholangiocarcinoma.

ESMO Gastrointest Oncol · 2025 · PMC12836708 · PMID 41646284

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendP = 0.060so close (0.05 < p ≤ 0.1)

4 In addition, in the ClarIDHy study, treatment with ivosidenib showed a trend for improved overall survival (OS) compared with placebo (HR = 0.69; 95% CI 0.44–1.10; P = 0.060; median OS 10.8 months versus 9.7 months, respectively), which was considered significant after adjusting for patient crossover from placebo to ivosidenib using the rank-preserving structural failure ti

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Quantitative benefit-risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with m&lt;i&gt;IDH1&lt;/i&gt; cholangiocarcinoma.

The sentences

Quantitative benefit-risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with m<i>IDH1</i> cholangiocarcinoma.